Cell Science

Fluorescent Immunohistochemistry
#Assays #Cell Science #Drug discovery #Drug targets #Immunohistochemistry

Find validated IHC and mIF markers for your target before your study starts

This new free download can help researchers avoid assay development delays. Download this reference list from Crown Bioscience, which shows what is already validated and ready to run. You will learn: 500+ Human IHC markers for RUO, IVD or CDx Prevalidated 5 to 7-color mIF panels suitable for IO and… Read More

#News

T cell engagers
#Cell Science #Drug discovery #T cell engagers #Whitepaper

Whitepaper – T-cell engagers: From drug discovery hurdles to next-gen solutions

Read this new Whitepaper from WuXi Biologics. Innovative platforms across key stages of TCE drug discovery, with real-world case studies on high-purity production and fit-for-purpose in vitro & in vivo studies. Proven approaches to navigate key development challenges, such as structural complexity, CRS risks, and tumour heterogeneity. Forward-looking strategies combining… Read More

#News

#Drug discovery #Lightcast Discovery #Single-cell analysis

Bringing functional single-cell analysis into drug discovery 

Sarah Taylor, VP of Science at Lightcast, discusses how functional single-cell analysis can complement existing technologies, improve early-stage drug discovery decisions and help researchers identify promising candidates by measuring what cells do.  DDW: You spent nearly nine years at 10x Genomics taking genomic technologies from concept to launch, and… Read More

#Exclusive Content

#Advertorial #HUB Organoids #KRAS #Organoids

KRAS is no longer undruggable. Is your preclinical model ready?

In this paid-for advertorial for the Fall 2026 issue of DDW, HUB Organoids shares insight on KRAS inhibitor development.  KRAS inhibitor development has moved past single-allele chemistry into pan-RAS and combination strategies. HUB Organoids’ patient-derived organoid platform gives your programme the resistance data, allele breadth, and combination… Read More

#Exclusive Content

#Biologics #Cell Science #Drug discovery #Stability characterisation

Stop settling for the proxy – Why stability tests for biologics should measure intermolecular interactions directly

In this advertorial, Dr John Stenson from Malvern Panalytical explains why we need to move away from using ‘SLS mode’ on DLS instruments to determine B22 stability values for biologics. Reliable stability data: A growing need Stability testing for biologics is undergoing something of a revolution, with the… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Drug discovery #Infectious diseases #Lab automation #Organoids #UK

New robotic AI lab opens in Liverpool to help fight infectious diseases  

The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool.   The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More

#News

Human liver
#Cell Science #Drug discovery #New approach methodologies (NAMs) #Organoids #Preclinical development

Download the Factsheet: MASLD research needs better liver models

A new resource is now available to download for free. MASLD drug development is limited by models that don’t reflect human liver biology. HUB’s patient-derived liver organoids retain donor genetics, architecture and physiology. Download the Factsheet to learn: How organoids recapitulate steatosis and fibrosis Which readouts support target validation… Read More

#News

#Cancer drug targets #Clinical trial #DNA #Kairos Pharma #Prostate cancer #Stem cells #Tumour biology

Cancer drug resistance isn’t one problem, it’s many

Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it.  Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More

#Cancer Research #Exclusive Content

TARGA imager
#Neurodevelopmental disorders #Organoids #Schizophrenia

Neurodevelopmental imaging in schizophrenia 

This paid-for advertorial by Lumencor appeared in DDW Volume 27 – Issue 3, Summer 2026. Studying neurodevelopmental disorders like schizophrenia is limited by model complexity and tissue access. Advanced stem cell models combined with high-speed imaging now enable scalable insight into neuronal activity and network behaviour. … Read More

#Exclusive Content

Organoid
#3D cell culture #Drug discovery #New approach methodologies (NAMs) #Oncology #Organoids

Why traceability will make or break the organoid revolution 

By Carolina Lucchesi, Principal Scientist and Head of Microphysiological Systems, ATCC.  Across the world, regulators are sending a consistent signal: the era of animal-only preclinical testing is drawing to a close. In the United States, the Food and Drug Administration (FDA) has committed to phasing out animal testing requirements1. The European Union and United Kingdom are moving in the… Read More

#Exclusive Content

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

HUB Organoids Fact Sheet
#Fact Sheet #Organoids

New Fact Sheet: Liver organoid platform for predictive hepatotoxicity assessment

A new Fact Sheet is now available to download from HUB Organoids (now part of Merck). Get earlier, mechanistic insight into DILI risk with HUB Organoids’ human liver organoid platform: Donor-diverse liver organoid biobank Multiparametric live-cell assay: mitochondrial dysfunction, oxidative stress, lipid dysregulation,viability Supports lead optimisation and safer candidate selection… Read More

#News